CellaVision AB (publ) (CELLAVISION AB CELLAVISION ORD ) aksje

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. Further, it offers reagents to identify cell and tissue morphology, parasites, and bacteria in diagnosing various diseases; and instruments, including RAL SmearBox, RAL Stainbox, and RAL Stainer. The company sells its products to hospital and commercial laboratories. The company was incorporated in 1994 and is headquartered in Lund, Sweden.